For the Inventor, By the Inventor

Enter assignee name

Tokushima, Japan

Delta-fly Pharma, Inc.

USPTO Granted Patents = 14

EPO Patents = 14

Trademarks = 2

Forward Citations = 2

Loading Chart...

Loading Chart...

10 inventors (with patents filed for the assignee):

Tatsuhiro Ishida (7 out of 11 patents)

Kiyoshi Eshima (7 out of 9 patents)

Hiromi Wada (6 out of 10 patents)

4. Masakazu Fukushima (3 out of 43 patents)

5. Cheng Long Huang (2 out of 2 patents)

6. Ryo Oyama (1 out of 1 patent)

7. Shotaro Watanabe (1 out of 1 patent)

8. Takahiro Hatakeyama (1 out of 1 patent)

9. Shozo Yamada (1 out of 13 patents)

10. Reo Hamaguchi (1 out of 1 patent)

11. Kazuhito Arakawa (1 patent)

12. Eshima Kiyoshi (0 patent)

13. Ishida Tatsuhiro (0 patent)

14. Wada Hiromi (0 patent)

15. Hamaguchi Reo (0 patent)

14 patents: Sort by Forward Citations

1. 11957701 - Therapy and new therapeutic agent for blood cancer (2024-04-16),

2. 11684582 - Method for stabilizing humidity-sensitive pharmaceutical substance and stabilized preparation thereof (2023-06-27),

3. 11622976 - Urine alkali agent useful for treatment of cancer patient (2023-04-11),

4. 11524078 - Water-soluble macromolecular derivative of Venetoclax (2022-12-13),

5. 11246847 - Anticancer drug effect enhancer (2022-02-15),

6. 11185517 - Pharmaceutical composition for treatment or remission of chronic myelogenous leukemia (2021-11-30),

7. 10293019 - Pharmaceutical composition for treatment of or remission in elderly or terminal cancer patient (2019-05-21),

8. 10111955 - PEG derivative (2018-10-30),

9. 9855345 - Method for producing lipoplex for topical administration and antitumor agent using such lipoplex (2018-01-02),

10. 9745583 - Liposome for topical administration and application thereof (2017-08-29),

11. 8889699 - 5-fluorouracil derivative (2014-11-18),

12. 8592572 - Liposome containing shRNA molecule targeting a thymidylate synthase and use thereof (2013-11-26),

13. 8524876 - RNAi molecule targeting thymidylate synthase and application thereof (2013-09-03),

14. 8377905 - Stable crystal of 1-(2'-cyano-2′-deoxy-β-D-arabinofuranosyl)cytosine monohydrochloride (2013-02-19),

Delta-Fly Pharma, Inc. is a leading pharmaceutical company specializing in the development and manufacturing of innovative medicines. With cutting-edge research capabilities and state-of-the-art manufacturing facilities, we aim to provide advanced healthcare solutions to patients worldwide. We prioritize quality, safety, and efficacy in our products, working closely with regulatory agencies to ensure compliance with industry standards. Our dedicated team of scientists, researchers, and professionals are committed to improving patient outcomes and making a positive impact on global healthcare. Visit our website to learn more about our products and our commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

14 Patents

#8 in Tokushima

#3,493 in Japan

#40,935 in the World

Tokushima, Japan

Delta-fly Pharma, Inc.

Forward Citations = 2

10 inventors:

Tatsuhiro Ishida (7 out of 11 patents)

Kiyoshi Eshima (7 out of 9 patents)

Hiromi Wada (6 out of 10 patents)

4. Masakazu Fukushima (3 out of 43 patents)

5. Cheng Long Huang (2 out of 2 patents)

Please report any incorrect information to support@idiyas.com

Loading…